The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus.

Abstract

Successful management of prediabetes and type 2 diabetes mellitus (T2DM) requires a multifaceted, multidisciplinary approach that involves patient education and support, lifestyle modification, and appropriate use of pharmacologic interventions with frequent monitoring and adjustment to ensure that target goals for hyperglycemia, dyslipidemia, and hypertension are achieved and maintained. Studies have shown that the bile acid sequestrant colesevelam HCl reduces hemoglobin A1c and low-density lipoprotein-cholesterol levels in patients with prediabetes and T2DM. This article briefly reviews current treatment guidelines for patients with prediabetes and T2DM and the potential role of colesevelam in the management of prediabetes and T2DM with oral antidiabetes agents.

• Authors: Philip Levy, Paul S Jellinger
• Journal: Postgraduate medicine (Postgrad Med) Vol. 122 Issue 3Suppl Pg. 1-8 (May 2010) ISSN: 1941-9260 [Electronic] England
• PMID: 20581432 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anticholesteremic Agents
• Blood Glucose
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Allylamine
• Colesevelam Hydrochloride

Topics

• Administration, Oral
• Aged
• Allylamine (administration & dosage, analogs & derivatives)
• Anticholesteremic Agents (administration & dosage)
• Blood Glucose (analysis)
• Cardiovascular Diseases (prevention & control)
• Colesevelam Hydrochloride
• Diabetes Mellitus, Type 2 (blood, diagnosis, drug therapy)
• Drug Therapy, Combination
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (administration & dosage)
• Male
• Middle Aged
• Practice Guidelines as Topic
• Prediabetic State (blood, diagnosis, drug therapy)
• Prognosis
• Severity of Illness Index
• Treatment Outcome